Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Clinical proteomics application
- Study design: clinical aspect
- Bacterial over-growth in urine affects proteomics
- Sample size and statistical analysis matters!
- European kidney and urine proteomics (EuroKUP)
- EuroKUP four working groups
- Initiatives
- Scientific reporting of proteomic biomarker
- Biomarker characterization
- Clinical proteomics approaches
- Bladder cancer statistics
- Bladder cancer pathology
- Current diagnostic tools for bladder cancer
- Biomarker needs for bladder cancer
- Identifying aggressive bladder cancer biomarkers
- Why urine?
- Identification of urine proteome
- IMAC fractionation workflow for urinary proteins
- Bladder cancer biomarkers by IMAC fractionation
- Proteins identified in bladder cancer samples
- Confirmation of expression differences by WB
- TMA for profilin 1
- Profilin expression and disease outcome
- Profilin blockage
- Cell line models for bladder cancer (T24M)
- Development of a cell line model
- T24M increased tumorigenic properties in vivo
- Secretome analysis for protein expression
- Protein expression in secretome: T24 vs. TS24M
- Western blot and activity assay
- SPARC Ab decreases T24M motility in vitro
- Summary
- Promising bladder cancer biomarkers
- Clinical impact in bladder cancer management
- From biomarker discovery to implementation
- Guidelines for biomarker discovery
- Getting closer to implementation
- Roadmap to clinical implementation
- Biomarker discovery: hypothesis driven
- Multi-disciplinary collaborations
- Acknowledgements
- Funding sources
- Thank you
Topics Covered
- Clinical proteomics: principles of experimental design and data reporting
- Clinical needs in bladder cancer
- Bladder Cancer Biomarker discovery in urine using proteomics approaches
- How to progress towards implementation
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Vlahou, A. (2013, November 5). Clinical proteomics in the investigation of bladder cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/SWTL8916.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Antonia Vlahou has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.